Company Description
FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs.
Its lead product candidates are Pamrevlumab, a human monoclonal antibody targeting connective tissue growth factor that is in Phase III clinical development for the treatment of locally advanced pancreatic cancer; and Roxadustat, an oral small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase activity, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in China, Europe, Japan, and other countries, as well as in Phase III clinical development for anemia related with myelodysplastic syndromes.
The company has collaboration agreements with Astellas Pharma Inc. and AstraZeneca AB. FibroGen, Inc. was incorporated in 1993 and is headquartered in San Francisco, California.
| Country | United States |
| Founded | 1993 |
| IPO Date | Nov 14, 2014 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 486 |
| CEO | Thane Wettig |
Contact Details
Address: 409 Illinois Street San Francisco, California 94158 United States | |
| Phone | 415 978 1200 |
| Website | fibrogen.com |
Stock Details
| Ticker Symbol | FGEN |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0000921299 |
| CUSIP Number | 31572Q808 |
| ISIN Number | US31572Q8087 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Thane Wettig | Chief Executive Officer and Director |
| David DeLucia | Chief Financial Officer |
| Michael D. Lowenstein J.D., Ph.D. | Chief Legal Officer |
| Julian N. Stern | Secretary |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Feb 24, 2025 | 8-K | Current Report |
| Feb 24, 2025 | 424B5 | Filing |
| Feb 20, 2025 | 8-K | Current Report |
| Feb 14, 2025 | SCHEDULE 13G/A | Filing |
| Feb 13, 2025 | SCHEDULE 13G/A | Filing |
| Dec 16, 2024 | 8-K | Current Report |
| Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Nov 12, 2024 | 10-Q | Quarterly Report |
| Nov 12, 2024 | 8-K | Current Report |
| Nov 12, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |